What is claimed:

1. A compound of formula (I):



(I)

wherein:

Ar is $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl, wherein each Ar is optionally substituted with one to four substituents selected from Z;

A is $-CH_2-$, -NH, -O-, or -S-;

R^1 is $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl; wherein each R^1 is optionally substituted with one to four substituents selected from Z^1;

Y is selected from the group consisting of $-(CH_2)_n-$, $-(CH_2)_n\text{-}NR^{15}-$, $-(CH_2)_n\text{-}O-$, and $-(CH_2)_n\text{-}S-$; wherein each n is independently 0, 1, 2, or 3;

and R^{15} is hydrogen, $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl; wherein each R^{15} is optionally substituted with one to four substituents selected from Z^2;

Q is selected from the group consisting of $-(CR^2R^3)_m-$, $-(CR^2R^3)_m\text{-}N^{15}-$, $-N^{15}\text{-}(CR^2R^3)_m-$, $(CR^2R^3)_m\text{-}O-$, $-O-(CR^2R^3)_m-$, $-S-(CR^2R^3)_m-$, and $-(CR^2R^3)_m\text{-}S-$; wherein each m is independently 1, 2, 3, 4, 5, or 6;

HET is a fused $(C_6\text{-}C_{12})$heteroaryl optionally substituted one to four substituents selected from Z^3, wherein Z^3 may be in any ring of the fused $(C_6\text{-}C_{12})$heteroaryl, having the formula:



i

or



ii ;

wherein the dotted lines are optional double bonds such that said fused $(C_6\text{-}C_{12})$heteroaryl is aromatic;

Each of X^1, X^2, W^1, W^2, W^3, W^4, B^1, B^2, B^3, B^4, D^1, D^2, D^3 and D^4 are independently =CH- or =N-;

At least one of X^1, X^2, B^1, B^2, B^3, and B^4 must be =N-;

At least one of W^1, W^2, W^3, W^4, D^1, D^2, D^3 and D^4 must be =N-;

Wherein each --c is a point of attachment to the group –Y- and each ---d is a point of attachment to the group –Q-;

Each of Z, Z^1, Z^2, and Z^3 are selected from the group consisting of:

(c) H, F, Cl, Br, I, CF_3, or CN;

(d) $(C_1\text{-}C_8)$alkyl optionally substituted with one to four substituents independently selected from R^7;

(c) -C(=O)-R^4 {wherein R^4 is selected from the group consisting of H, OH, CF_3, $(C_1\text{-}C_8)$alkyl, $(C_1\text{-}C_8)$alkyl-O-, $(C_3\text{-}C_{10})$cycloalkyl, $(C_3\text{-}C_{10})$cycloalkyl-O-; $(C_2\text{-}C_{10})$heterocyclyl, $(C_2\text{-}C_{10})$heterocyclyl-O-; $(C_6\text{-}C_{10})$aryl, $(C_6\text{-}C_{10})$aryl-O-, $(C_1\text{-}C_{10})$heteroaryl, and $(C_1\text{-}C_{10})$heteroaryl-O-};

(d) -C(=O)-NR^5R^6 {wherein R^5 is H or $(C_1\text{-}C_8)$alkyl; and wherein R^6 is selected from the group consisting of H, $(C_1\text{-}C_8)$alkyl, -CH_2-(C=O)-O-$(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl};

(j) $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl;

(k) NR^9R^{10} {wherein R^9 is independently H or $(C_1\text{-}C_8)$alkyl; R^{10} is selected from the group consisting of -C(=O)-O-$C(CH_3)_3$, $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl; or R^9 and R^{10} may optionally be taken together with the nitrogen to which they are attached to form a 5 to 8-membered heteroaryl or heterocyclyl ring};

(l) R^{11}-O- {wherein R^{11} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl};

(m) R^{12}-SO_p- {wherein R^{12} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl; and wherein p is 0,1, or 2}; and

(n) $R^{13}R^{14}$N-SO_q- {wherein R^{13} is H or $(C_1\text{-}C_8)$alkyl; R^{14} is $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl; or R^{13} and R^{14} may optionally be taken together with the nitrogen to which they are attached to form a 5 to 8-membered heteroaryl or heterocyclyl ring; and wherein q is 1 or 2};

Each of R^2 and R^3 is independently (a) H; (b) $(C_1\text{-}C_8)$alkyl optionally substituted with one to four substituents independently selected from R^7; (c) COOH; or (d) $(C_6\text{-}C_{10})$aryl optionally substituted with one to four substituents independently selected from R^8;

Wherein each of $R^7$and R^8 are independently selected from the group consisting of:

(g) F, Cl, Br, I, CN, CF_3, or NO_2;

(h) $-NR^9R^{10}$ {wherein R^9 is independently H or $(C_1\text{-}C_8)$alkyl; R^{10} is selected from the group consisting of $-C(=O)-O-C(CH_3)_3$, $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl; or R^9 and R^{10} may optionally be taken together with the nitrogen to which they are attached to form a 5 to 8-membered heteroaryl or heterocyclyl ring};

(i) R^{11}-O- {wherein R^{11} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl};

(j) $R^{12}\text{-}SO_p$- {wherein R^{12} is selected from the group consisting of $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, and $(C_1\text{-}C_{10})$heteroaryl; and wherein p is 0,1, or 2}; and

(k) $R^{13}R^{14}N\text{-}SO_q$- {wherein R^{13} is H or $(C_1\text{-}C_8)$alkyl; R^{14} is $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_2\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl, or $(C_1\text{-}C_{10})$heteroaryl; or R^{13} and R^{14} may optionally be taken together with the nitrogen to which they are attached to form a 5 to 8-membered heteroaryl or heterocyclyl ring; and wherein q is 1 or 2};

(l) T is selected from the group consisting of -(C=O)-OH, $-(C=O)-OR^{15}$, -(C=O)-OM {wherein M is an alkali metal or alkaline earth metal}, tetrazolyl, thiazolidinyl, $-SO_2\text{-}NH\text{-}R^{15}$, $-NH\text{-}SO_2\text{-}R^{15}$, $-(C=O)\text{-}NH\text{-}SO_2\text{-}R^{15}$, and other acid prodrug or isosteres thereof;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 wherein

HET is a fused $(C_6\text{-}C_{12})$heteroaryl optionally substituted one to four substituents selected from Z^3, wherein Z^3 may be in any ring of the fused $(C_6\text{-}C_{12})$heteroaryl, having the formula:



i selected from the group consisting of:



i(a) ;



i(b) ;



i(c) ;



i(d) ;



i(e) ;



i(f) ;



i(g) ;



i(h) ;



i(i) ;



i(j) ;



i(k) ;



i(l) ;



i(m) ;



i(n) ;



;



;



;

i(o) i(p) i(q)





i(r) ; and i(s) .

3. The compound according to claim 1 wherein

HET is a fused (C_6-C_{12})heteroaryl optionally substituted one to four substituents selected from Z^3, wherein Z^3 may be in any ring of the fused (C_6-C_{12})heteroaryl, having the formula:



selected from the group consisting of:







ii(a) ; ii(b) ; ii(c) ;



ii(d) ;



ii(e) ;



ii(f) ;



ii(g) ;and



ii(h) .

4. The compound according to claim 1 wherein said Ar is phenyl.

5. The compound according to claim 1 wherein said A is –O-.

6. The compound according to claim 1 wherein said R^1 is $(C_1\text{-}C_8)$alkyl.

7. The compound according to claim 1 wherein said R^1 is $(C_6\text{-}C_{10})$aryl.

8. The compound according to claim 1 wherein said Q is $-(CR^2R^3)_m$-, m is 2 or 3, and each of R^2 and R^3 is hydrogen or $(C_1\text{-}C_8)$alkyl.

9. The compound according to claim 1 wherein said Q is $-(CR^2R^3)_m$-NH-, m is 1 or 2, and each of R^2 and R^3 is hydrogen or unsubstituted $(C_1\text{-}C_8)$alkyl.

10. The compound according to claim 1 wherein said Q is $-(CR^2R^3)_m$-O-, m is 1 or 2, and each of R^2 and R^3 is hydrogen or unsubstituted $(C_1\text{-}C_8)$alkyl.

11. The compound according to claim 1 wherein said Q is $-(CR^2R^3)_m$-S-, m is 1 or 2, and each of R^2 and R^3 is hydrogen or unsubstituted $(C_1\text{-}C_8)$alkyl.

12. The compound according to claim 1 wherein said T is –(C=O)-OH.

13. The compound according to claim 1 wherein said T is selected from the group consisting of tetrazolyl, thiazolidinyl, $-SO_2\text{-NH-}R^{15}$, $-NH\text{-}SO_2\text{-}R^{15}$, $-(C=O)\text{-NH-}SO_2\text{-}R^{15}$, and other acid prodrug or isosteres thereof.

14. The compound according to claim 1 wherein said Z^3 is selected from the group consisting of F, Cl, Br, or I.

15. The compound according to claim 1 wherein said Z^3 is $(C_1\text{-}C_8)$alkyl.

16. The compound according to claim 1 wherein said Y is $-(CH_2)_n$-O- and n is 1, 2, or 3.

17. The compound according to claim 1 wherein said Y is $-(CH_2)_n-NR^{15}-$, wherein R^{15} is hydrogen, (C_1-C_8)alkyl or (C_3-C_{10})cycloalkyl, and n is 1, 2, or 3.

18. The compound according to claim 1 wherein said Y is $-(CH_2)_n-$ and n is 1, 2, or 3.

19. The compound according to claim 1 wherein said Y is $-(CH_2)_n-S-$ and n is 1, 2, or 3.

20. The compound according to claim 1 selected from the group consisting of:


;

;

;

;

;

;

;

;

;

;

and the pharmaceutically acceptable salts thereof.

21. A method of treating non-insulin dependent diabetes mellitus in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

22. The method of treating non-insulin dependent diabetes mellitus according to claim 21 wherein said mammal has an impaired glucose tolerance.

23. A method of treating polycystic ovarian syndrome in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

24. A method of treating obesity in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

25. A method of reducing body weight in an obese mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

26. A method of treating hyperglycemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

27. A method of treating hyperlipidemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

28. A method of treating hypercholesteremia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

29. A method of treating atherosclerosis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

30. A method of treating hypertriglyceridemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

31. A method of treating hyperinsulinemia in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

32. A method of treating a patient suffering from abnormal insulin and/or evidence of glucose disorders associated with circulating glucocorticoids, growth hormone, catecholamines, glucagon, or parathyroid hormone, comprising administering to said patient a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

33. A method of treating insulin resistance syndrome in humans comprising administering to a patient in need of treatment a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

34. A method of treating PPAR-related disorders in humans comprising administering to a patient in need of treatment a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

35. A method of modulating PPAR activity in a mammal, comprising administering to a mammal a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

36. A method of lowering blood glucose in a mammal, comprising administering to a mammal an amount of a fused heteroaryl compound according to claim 1 effective to lower blood glucose levels.

37. A method of modulating fat cell differentiation in a mammal, comprising administering to a mammal a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

38. A method of modulating processes mediated by PPAR in a mammal, comprising administering to a mammal a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

39. The method of modulating processes mediated by PPAR in a mammal according to claim 39, wherein said fused heteroaryl compound according to claim 1 is administered to said mammal in combination with at least one compound selected from the group consisting of α-glucosidase inhibitors, aldose reductase inhibitors, biguanide preparations, statin base compounds, squalene synthesis inhibitors, fibrate base compounds, LDL catabolism promoters and angiotensin-converting enzyme inhibitors.

40. A method of increasing insulin sensitivity in mammals, comprising administering to a mammal a therapeutically effective amount of a fused heteroaryl compound according to claim 1.

41. A composition comprising at least one modulator of PPAR according to claim 1 and a pharmaceutically acceptable carrier thereof.

42. A composition according to claim 40 further comprising at least one compound selected from the group consisting of α-glucosidase inhibitors, aldose reductase inhibitors, biguanide preparations, statin base compounds, squalene synthesis inhibitors, fibrate base compounds, LDL catabolism promoters and angiotensin-converting enzyme inhibitors.